N6-methyladenosine in hematological malignancies: a concise review.

IF 3.1 3区医学 Q2 HEMATOLOGY

Current Opinion in Hematology Pub Date : 2023-01-01 DOI:10.1097/MOH.0000000000000741

Wan-Jie Wang, Ting-Ting Xu, Jing Bao

{"title":"N6-methyladenosine in hematological malignancies: a concise review.","authors":"Wan-Jie Wang, Ting-Ting Xu, Jing Bao","doi":"10.1097/MOH.0000000000000741","DOIUrl":null,"url":null,"abstract":"Purpose of review: Hematological malignancies are a kind of systemic cancers mostly related to abnormal differentiation of blood stem cells. Because of the poor prognosis, chemotherapy resistance and common recurrence, new mechanisms and treatment therapies are looking forward to be discovered.Recent findings: Over the years, epigenetic abnormalities have been known to act a key part in occurrence and development of hematological tumors. In the internal modifications on long noncoding eukaryotic mRNA, there is a common type called N6-methyladenosine that can change the expression of target genes and participate in the translation, degradation and splicing of mRNA. M6A is related to a wealth of cancers, such as HNRNPA2B1's elevation in multiple myeloma, METTLE3's elevation in acute myeloid leukemia and lung cancer. Immune cells, playing a significant role in hematological cancers, can also be regulated by m6A.Summary: In the review, we summarized the recent progress on hematological malignancies associating with m6A and immune cells, which may offer a new road for the treatment of them.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOH.0000000000000741","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Hematological malignancies are a kind of systemic cancers mostly related to abnormal differentiation of blood stem cells. Because of the poor prognosis, chemotherapy resistance and common recurrence, new mechanisms and treatment therapies are looking forward to be discovered.

Recent findings: Over the years, epigenetic abnormalities have been known to act a key part in occurrence and development of hematological tumors. In the internal modifications on long noncoding eukaryotic mRNA, there is a common type called N6-methyladenosine that can change the expression of target genes and participate in the translation, degradation and splicing of mRNA. M6A is related to a wealth of cancers, such as HNRNPA2B1's elevation in multiple myeloma, METTLE3's elevation in acute myeloid leukemia and lung cancer. Immune cells, playing a significant role in hematological cancers, can also be regulated by m6A.

Summary: In the review, we summarized the recent progress on hematological malignancies associating with m6A and immune cells, which may offer a new road for the treatment of them.

查看原文本刊更多论文

n6 -甲基腺苷在血液系统恶性肿瘤中的作用:简明综述。

综述目的:血液学恶性肿瘤是一种主要与血液干细胞异常分化有关的全身性肿瘤。由于预后差，化疗耐药，易复发，期待发现新的发病机制和治疗方法。近年来，表观遗传异常在血液学肿瘤的发生和发展中起着关键作用。在真核生物长链非编码mRNA的内部修饰中，有一种常见的类型叫做n6 -甲基腺苷，它可以改变靶基因的表达，参与mRNA的翻译、降解和剪接。M6A与多种癌症有关，如HNRNPA2B1在多发性骨髓瘤中的表达升高，METTLE3在急性髓性白血病和肺癌中的表达升高。免疫细胞在血液学癌症中发挥重要作用，也可受m6A调控。摘要:本文综述了近年来与m6A和免疫细胞相关的血液恶性肿瘤的研究进展，以期为m6A和免疫细胞相关的血液恶性肿瘤的治疗提供新的思路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Hematology 医学-血液学

CiteScore

6.60

自引率

3.10%

发文量

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Hematology is an easy-to-digest bimonthly journal covering the most interesting and important advances in the field of hematology. Its hand-picked selection of editors ensure the highest quality selection of unbiased review articles on themes from nine key subject areas, including myeloid biology, Vascular biology, hematopoiesis and erythroid system and its diseases.